Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Erythropoietin improves quality of life--a response.
Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Bottomley A, et al. Lancet Oncol. 2002 Sep;3(9):527. doi: 10.1016/s1470-2045(02)00844-6. Lancet Oncol. 2002. PMID: 12217788 No abstract available.
Assessing HRQOL: a neglected issue for high-grade glioma.
Efficace F, Bottomley A. Efficace F, et al. Among authors: bottomley a. Lancet Oncol. 2003 Jan;4(1):11-2. doi: 10.1016/s1470-2045(03)00955-0. Lancet Oncol. 2003. PMID: 12517534 No abstract available.
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M; European Organization for Research and Treatment of Cancer Breast Cancer Group. Bottomley A, et al. J Clin Oncol. 2004 Jul 1;22(13):2576-86. doi: 10.1200/JCO.2004.02.037. J Clin Oncol. 2004. PMID: 15226325 Clinical Trial.
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Shepherd L, de Haes H, Sprangers MA, Bottomley A. Efficace F, et al. Among authors: bottomley a. J Clin Oncol. 2004 Aug 15;22(16):3381-8. doi: 10.1200/JCO.2004.02.060. J Clin Oncol. 2004. PMID: 15310784 Clinical Trial.
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, Welnicka-Jaskiewicz M, Mauriac L, Dyczka J, Cufer T, Lichinitser MR, Schornagel JH, Bonnefoi H, Shepherd L; European Organisation for Research and Treatment of Cancer Breast Cancer Group; National Cancer Institute of Canada; Swiss Group for Clinical Cancer Research. Bottomley A, et al. Lancet Oncol. 2005 May;6(5):287-94. doi: 10.1016/S1470-2045(05)70100-5. Lancet Oncol. 2005. PMID: 15863376 Clinical Trial.
300 results